We demonstrate that ComBiNE is efficacious in a BRCA‐mutant breast cancer model, by editing the RAD52 gene and inhibiting PARP, leading to substantial anti‐tumor effects in vivo. This evidence concerns the gene RAD52 and breast carcinoma.